These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

134 related items for PubMed ID: 3297875

  • 21. Mycobacterium avium subsp. paratuberculosis-specific mpt operon expressed in M. bovis BCG as vaccine candidate.
    Heinzmann J, Wilkens M, Dohmann K, Gerlach GF.
    Vet Microbiol; 2008 Aug 25; 130(3-4):330-7. PubMed ID: 18343053
    [Abstract] [Full Text] [Related]

  • 22. Antigenic cross-reactivity between Mycobacterium bovis (BCG) and Leishmania donovani.
    Smrkovski LL, Larson CL.
    Infect Immun; 1977 Nov 25; 18(2):561-2. PubMed ID: 336551
    [Abstract] [Full Text] [Related]

  • 23. Pathogenesis of pulmonary Mycobacterium bovis infection: basic principles established by the rabbit model.
    Dannenberg AM.
    Tuberculosis (Edinb); 2001 Nov 25; 81(1-2):87-96. PubMed ID: 11463228
    [No Abstract] [Full Text] [Related]

  • 24. Consequence of prior exposure to environmental mycobacteria on BCG vaccination and diagnosis of tuberculosis infection.
    Thom M, Howard C, Villarreal-Ramos B, Mead E, Vordermeier M, Hope J.
    Tuberculosis (Edinb); 2008 Jul 25; 88(4):324-34. PubMed ID: 18329343
    [Abstract] [Full Text] [Related]

  • 25. [The formation of delayed hypersensitivity to mycobacterial antigens].
    Liashchenko KP, Bobrovnik SA, Komissarenko SV.
    Zh Mikrobiol Epidemiol Immunobiol; 1991 Apr 25; (4):66-8. PubMed ID: 1882613
    [Abstract] [Full Text] [Related]

  • 26. Use of sodium deoxycholate to extract cell wall components of virulent Mycobacterium bovis.
    Hall MR, Thoen CO.
    Am J Vet Res; 1986 Dec 25; 47(12):2572-6. PubMed ID: 3541707
    [Abstract] [Full Text] [Related]

  • 27. Studies on diagnostic potential of secretory antigens of Mycobacterium bovis.
    Trivedi S, Das SK, Kumar R, Chandra R.
    Indian J Exp Biol; 2006 Jan 25; 44(1):14-8. PubMed ID: 16430085
    [Abstract] [Full Text] [Related]

  • 28. First data on Eurasian wild boar response to oral immunization with BCG and challenge with a Mycobacterium bovis field strain.
    Ballesteros C, Garrido JM, Vicente J, Romero B, Galindo RC, Minguijón E, Villar M, Martín-Hernando MP, Sevilla I, Juste R, Aranaz A, de la Fuente J, Gortázar C.
    Vaccine; 2009 Nov 12; 27(48):6662-8. PubMed ID: 19747578
    [Abstract] [Full Text] [Related]

  • 29. [Isolation of species-specific Mycobacterium bovis antigen and testing of its cutaneous tuberculin activity].
    Liashchenko KP, Bobrovnik SA, Komissarenko SV.
    Probl Tuberk; 1991 Nov 12; (8):12-4. PubMed ID: 1722040
    [Abstract] [Full Text] [Related]

  • 30. Proceedings: Cross reactions between mycobacterial antigens.
    Rees RJ.
    Ann Sclavo; 1971 Nov 12; 13(6):430-46. PubMed ID: 5005892
    [No Abstract] [Full Text] [Related]

  • 31. Environmental strains of Mycobacterium avium interfere with immune responses associated with Mycobacterium bovis BCG vaccination.
    Young SL, Slobbe L, Wilson R, Buddle BM, de Lisle GW, Buchan GS.
    Infect Immun; 2007 Jun 12; 75(6):2833-40. PubMed ID: 17371857
    [Abstract] [Full Text] [Related]

  • 32. [Experimental study of BCG-M vaccine with a lowered antigen dose].
    Iablokova TB, Pisarenko NN, Levi DT, Kazachkova TE, Nesterenko LA.
    Probl Tuberk; 1985 Jun 12; (6):52-5. PubMed ID: 3900992
    [No Abstract] [Full Text] [Related]

  • 33. [Activity and specificity of tuberculins derived from BCG culture filtrates].
    Levi DT, Iablokova TB, Altynova MP, Mitinskaia LA, Bardina EE.
    Probl Tuberk; 1985 Jun 12; (9):60-3. PubMed ID: 3906644
    [No Abstract] [Full Text] [Related]

  • 34. The ultrastructure of the strain BCG 725 cultivated on Sauton's medium with casein hydrolysate. Co-report the report "biochemistry of BCG lipids and their role in antituberculous immunity and hypersensitivity.
    Mohelská H.
    J Hyg Epidemiol Microbiol Immunol; 1975 Jun 12; 19(4):453-7. PubMed ID: 1107418
    [No Abstract] [Full Text] [Related]

  • 35. Protection against tuberculosis induced by oral prime with Mycobacterium bovis BCG and intranasal subunit boost based on the vaccine candidate Ag85B-ESAT-6 does not correlate with circulating IFN-gamma producing T-cells.
    Badell E, Nicolle F, Clark S, Majlessi L, Boudou F, Martino A, Castello-Branco L, Leclerc C, Lewis DJ, Marsh PD, Gicquel B, Winter N.
    Vaccine; 2009 Jan 01; 27(1):28-37. PubMed ID: 18977269
    [Abstract] [Full Text] [Related]

  • 36. Strain to strain variation in the immunogenicity of BCG.
    Grange JM, Gibson JA.
    Dev Biol Stand; 1986 Jan 01; 58 ( Pt A)():37-41. PubMed ID: 3297872
    [Abstract] [Full Text] [Related]

  • 37. [Isolation of MPB63 in the culture fluid of Mycobacterium bovis BCG Tokyo: genetical and immunological characterization].
    Kawajiri K.
    Kekkaku; 2003 Feb 01; 78(2):69-78. PubMed ID: 12664443
    [Abstract] [Full Text] [Related]

  • 38. Results of the study of the W 115 M. tuberculosis vaccine strain and the lyophilized experimental vaccine W 115.
    Weiszfeiler JG.
    J Hyg Epidemiol Microbiol Immunol; 1975 Feb 01; 19(4):492-7. PubMed ID: 812909
    [No Abstract] [Full Text] [Related]

  • 39. Delayed skin reactivity to carbohydrate and protein fractions of Mycobacterium bovis (BCG) culture filtrate in the absence and presence of serum antibody.
    Baer H, Chaparas SD.
    J Immunol; 1966 Feb 01; 96(2):353-7. PubMed ID: 4956650
    [No Abstract] [Full Text] [Related]

  • 40. An experimental model for immunotherapy of cancer.
    Zbar B, Ribi E, Rapp HJ.
    Natl Cancer Inst Monogr; 1973 Dec 01; 39():3-9. PubMed ID: 4595326
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.